2016
DOI: 10.2147/ijctm.s98418
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Platelet (PLT) transfusions are used for both treatment of bleeding and preventing bleeding in patients with thrombocytopenia and/or functionally abnormal PLTs. To ensure the efficacy of transfused PLTs, they must be stored at room temperature. Due to this storage requirement, PLTs have a short shelf life compared with other blood components of up to 5-7 days to minimize the risk of bacterial contamination. This short shelf life can lead to PLT shortages at times of increased demand or reduced supply and also … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 49 publications
(73 reference statements)
0
4
0
Order By: Relevance
“…Patients receiving PCC were transfused with less allogeneic blood products and had less multiple organ failure but had no survival benefit. Further evidence of non‐FFP/PLT use has been growing and experimental research is under way, such as in transfusion of cold‐stored and frozen PLTs, fibrinogen concentrate administration, and cryoprecipitate and the use of antifibrinolytic drugs such as tranexamic acid …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Patients receiving PCC were transfused with less allogeneic blood products and had less multiple organ failure but had no survival benefit. Further evidence of non‐FFP/PLT use has been growing and experimental research is under way, such as in transfusion of cold‐stored and frozen PLTs, fibrinogen concentrate administration, and cryoprecipitate and the use of antifibrinolytic drugs such as tranexamic acid …”
Section: Discussionmentioning
confidence: 99%
“…Patients receiving PCC were transfused with less allogeneic blood products and had less multiple organ failure but had no survival benefit. Further evidence of non-FFP/PLT use has been growing and experimental research is under way, such as in transfusion of cold-stored and frozen PLTs, 88,89 fibrinogen concentrate administration, [14][15][16][17]90,91 and cryoprecipitate [14][15][16][17]92 and the use of antifibrinolytic drugs such as tranexamic acid. [14][15][16][17][93][94][95] Strengths and weaknesses of this review and future research This is the first meta-analyses to report exposure to allogeneic blood products in resuscitation using fixed component transfusion ratios.…”
Section: Discussion Main Findingsmentioning
confidence: 99%
“…Platelets are currently routinely stored at room temperature (20–24 °C) and are stored for only 5–7 days because of the risk of bacterial contamination and deleterious changes with prolonged storage (Aubron et al, ). Wastage due to time expiry is a major issue.…”
Section: Blood Component and Coagulation Factor Supportmentioning
confidence: 99%
“…Clinical trials in other settings are underway. Frozen and cold‐stored platelets have major potential advantages for inventory management with improved availability and reduced wastage (Aubron et al, ).…”
Section: Blood Component and Coagulation Factor Supportmentioning
confidence: 99%